Sofosbuvir improves HCV-induced insulin resistance by blocking IRS1 degradation.

Rey, EstherAmpuero, JavierMolina-Jiménez, FranciscaMarañón, PatriciaGarcía-García, YaizaMúñoz-Hernández, RocíoRomero-Gómez, ManuelGarcía-Monzón, CarmeloMajano, PedroGonzález-Rodríguez, Águeda2025-01-072025-01-0720212001-1326https://hdl.handle.net/10668/27345enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Antiviral AgentsFemaleHepatitis CHumansInsulin Receptor Substrate ProteinsInsulin ResistanceMaleMiddle AgedSofosbuvirTreatment OutcomeSofosbuvir improves HCV-induced insulin resistance by blocking IRS1 degradation.research article33463051open access10.1002/ctm2.275PMC7810262https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ctm2.275https://pmc.ncbi.nlm.nih.gov/articles/PMC7810262/pdf